Immunomodulatory drug treats psoriasis by a new mechanism: the selective deactivation of TYK2 through its catalytically defective domain, the pseudokinase.
This is a preview of subscription content, log in via an institution to check access.
Change history
12 January 2023
In the version of this article initially published online, the reported status of Nimbus Therapeutics’ drug candidate NDI-034858 was incomplete and has now been updated, and the number of trial participants corrected to 259 people from 250. The changes have been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. TYK2-blocking agent showcases power of atypical kinase. Nat Biotechnol 40, 1701–1704 (2022). https://doi.org/10.1038/s41587-022-01602-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01602-w
- Springer Nature America, Inc.